Enanta Pharmaceuticals, Inc. filed a Form 8-K on October 28, 2026, disclosing that President and Chief Executive Officer Jay R. Luly, Ph.D., intends to retire by February 1, 2027, after 23 years with the company, and that Tara L. Kieffer, Ph.D., has been appointed to the newly created role of Chief Operating Officer.

Key Highlights

  • CEO retirement announced: Jay R. Luly, Ph.D., age 70, announced his intention to retire as President and Chief Executive Officer by February 1, 2027, following 23 years of leadership with the company.
  • Strategic advisor role planned: The company expects to enter into an agreement with Dr. Luly for his continued service as a strategic advisor for the remainder of 2027.
  • Successor search initiated: The Board of Directors has initiated a comprehensive search for Dr. Luly's successor, considering both internal and external candidates.
  • New COO appointed: Tara L. Kieffer, Ph.D., age 48, was appointed to the newly created role of Chief Operating Officer, effective October 28, 2026.
  • Dr. Kieffer's background: According to the filing, Dr. Kieffer joined Enanta in 2020 and most recently served as the company's Chief Product Strategy Officer.
  • No compensatory arrangements disclosed: The filing states that Dr. Kieffer "has not entered into any material plan, contract, arrangement or amendment in connection with this appointment."

Enanta Pharmaceuticals Announces Leadership Transition and New COO Appointment

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), headquartered in Watertown, Massachusetts, disclosed a significant leadership change on October 28, 2026, via a current report filed under Item 5.02. According to the filing, Jay R. Luly, Ph.D., age 70, announced his intention to retire as President and Chief Executive Officer by February 1, 2027. The filing notes that Dr. Luly has served in a leadership capacity with the company for 23 years.

The company disclosed that it expects to enter into an agreement with Dr. Luly for his continued service as a strategic advisor for the remainder of 2027 following his retirement. Separately, the Board of Directors has initiated a comprehensive search for Dr. Luly's successor, with the filing specifying that both internal and external candidates are being considered.

Also on October 28, 2026, the Board appointed Tara L. Kieffer, Ph.D., age 48, to the newly created role of Chief Operating Officer. The filing states that Dr. Kieffer joined Enanta in 2020 and most recently served as the company's Chief Product Strategy Officer. The filing also states there is no family relationship between Dr. Kieffer and any director or executive officer of the company, and that Dr. Kieffer does not have a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. The company's press release announcing both the planned retirement and the COO appointment was furnished as Exhibit 99.1 to the filing.

What Was Disclosed

Enanta Pharmaceuticals reported the planned retirement of President and CEO Jay R. Luly, Ph.D., by February 1, 2027, a forthcoming strategic advisor arrangement, a Board-led CEO search, and the appointment of Tara L. Kieffer, Ph.D., as Chief Operating Officer.